Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares in the company, valued at $623,250. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 47.90 on Thursday. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of 24.17 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a 52-week low of $17.25 and a 52-week high of $49.95. The company has a 50-day moving average price of $43.82 and a 200-day moving average price of $37.23.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The company had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. On average, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/09/14/insider-selling-supernus-pharmaceuticals-inc-supn-svp-sells-249300-00-in-stock.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. BlackRock Inc. boosted its position in shares of Supernus Pharmaceuticals by 156,173.3% during the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock valued at $209,595,000 after purchasing an additional 6,692,025 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Supernus Pharmaceuticals by 39.1% during the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after purchasing an additional 984,200 shares in the last quarter. Emerald Advisers Inc. PA bought a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $21,474,000. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $17,553,000. Finally, Hodges Capital Management Inc. bought a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $17,220,000. Institutional investors own 95.38% of the company’s stock.

A number of brokerages recently issued reports on SUPN. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Piper Jaffray Companies reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Cowen and Company reiterated a “positive” rating and issued a $50.00 target price (up from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. Finally, Janney Montgomery Scott began coverage on Supernus Pharmaceuticals in a report on Friday, July 14th. They issued a “neutral” rating and a $47.00 target price on the stock. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $48.29.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.